When most people think of leukemia diagnosis, they picture blood draws and bone marrow biopsies — not CT scanners or MRI machines. But imaging plays a surprisingly critical role in leukemia, from detecting organ involvement and enlarged lymph nodes to monitoring treatment response and catching relapse early. While imaging alone can’t diagnose leukemia (that still requires a peripheral blood smear and bone marrow biopsy showing ≥20% blasts for acute leukemia), it provides essential context that shapes every treatment decision.
This article examines leukemia through the lens of imaging — what each modality shows, when clinicians order specific scans, and what findings on imaging actually mean for prognosis and staging. Whether you’re a medical student studying hematologic malignancies, a radiology trainee, or a patient trying to understand why your oncologist ordered a PET/CT, this is the practical breakdown you need.
Why Imaging Matters in a “Liquid” Cancer
Leukemia is fundamentally different from solid tumors. There’s no primary mass to measure, no tumor margins to define. So why image at all? Three reasons:
- Extramedullary disease: Leukemia cells can infiltrate the spleen, liver, lymph nodes, central nervous system, skin, and even bones. Imaging maps this involvement.
- Treatment complications: Chemotherapy-induced immunosuppression leads to infections (fungal lung disease, typhlitis) that require urgent imaging to diagnose.
- Baseline and response assessment: Particularly in lymphocytic leukemias with significant lymphadenopathy, imaging documents disease burden before and after treatment.
Imaging Modalities Used in Leukemia: What Each One Shows
| Imaging Modality | Primary Use in Leukemia | Key Findings | Limitations |
|---|---|---|---|
| CT (with contrast) | Lymphadenopathy, organomegaly, infection workup | Enlarged spleen (>13 cm), bulky lymph nodes, hepatomegaly, pulmonary infiltrates | Radiation exposure; poor for bone marrow assessment |
| PET/CT (FDG) | Staging aggressive lymphoid leukemias, detecting extramedullary disease | Hypermetabolic lymph nodes, splenic uptake, chloromas (granulocytic sarcomas) | Variable FDG avidity across leukemia subtypes; CLL often PET-negative |
| MRI | Bone marrow infiltration, CNS involvement | Diffuse marrow signal abnormality on T1 (low signal replacing normal fat), leptomeningeal enhancement | Time-consuming; limited availability; motion artifact in sick patients |
| Ultrasound | Splenomegaly, hepatomegaly, superficial lymphadenopathy | Spleen size measurement, lymph node architecture, testicular infiltration in ALL relapse | Operator-dependent; can’t assess deep structures well |
| Chest X-ray | Mediastinal mass (T-ALL), infection screening | Anterior mediastinal widening, pleural effusions, pneumonia | Low sensitivity for subtle findings |
Imaging Findings by Leukemia Type
Acute Myeloid Leukemia (AML)
Chloromas (also called granulocytic sarcomas or myeloid sarcomas) are the hallmark imaging finding in AML. These are solid masses of leukemic cells that form outside the bone marrow — in the orbit, spine, skin, or soft tissues. On CT, they appear as homogeneous soft-tissue masses. On PET/CT, they’re intensely FDG-avid. Chloromas occur in roughly 2-8% of AML cases and can occasionally present before the bone marrow shows overt leukemia.
MRI of the spine in AML often reveals diffuse T1 hypointensity throughout the vertebral bodies, reflecting complete replacement of normal fatty marrow by leukemic blasts. This finding can be dramatic — and is sometimes the first clue on an MRI ordered for back pain.
Acute Lymphoblastic Leukemia (ALL)
In T-cell ALL, a mediastinal mass is present in up to 60-75% of cases, often visible on plain chest X-ray as anterior mediastinal widening. This can cause superior vena cava syndrome — a medical emergency. CT confirms the mass and evaluates airway compression.
CNS imaging with MRI with gadolinium is essential in ALL, since CNS involvement occurs in 5-10% of adult ALL at diagnosis. Leptomeningeal enhancement, cranial nerve thickening, or parenchymal masses may be visible, though a negative MRI doesn’t rule out CNS disease — lumbar puncture with cytology remains the gold standard.
Chronic Lymphocytic Leukemia (CLL)
CLL is the leukemia most likely to present with bulky lymphadenopathy visible on imaging. CT commonly shows diffuse lymphadenopathy in cervical, axillary, mediastinal, and retroperitoneal chains, along with splenomegaly. PET/CT becomes particularly important when Richter transformation (conversion to aggressive diffuse large B-cell lymphoma) is suspected — a focal area of intense FDG uptake (SUV >5-10) in a CLL patient should raise immediate concern.
Chronic Myeloid Leukemia (CML)
The classic imaging finding in CML is massive splenomegaly — spleens can reach 20-25 cm or more, sometimes filling the entire left abdomen. Ultrasound or CT easily quantifies this. In the era of tyrosine kinase inhibitors (imatinib and successors), monitoring splenic regression on imaging serves as an indirect marker of treatment response.
Imaging for Treatment Complications
Arguably, imaging is used even more frequently during leukemia treatment than at diagnosis. Neutropenic patients (ANC <500 cells/µL) undergoing induction chemotherapy are at extreme risk for opportunistic infections.
- Invasive pulmonary aspergillosis: CT shows the classic “halo sign” — a ground-glass opacity surrounding a pulmonary nodule. This finding in a febrile neutropenic patient warrants immediate antifungal therapy.
- Typhlitis (neutropenic enterocolitis): CT demonstrates cecal wall thickening >4 mm with surrounding fat stranding. Mortality can reach 50% if untreated.
- Fungal sinusitis: CT or MRI of the sinuses in patients with facial pain and prolonged neutropenia can reveal bony erosion suggestive of mucormycosis — a surgical emergency.
Emerging Imaging Techniques
Whole-body diffusion-weighted MRI (WB-DWI) is gaining traction as a radiation-free alternative to PET/CT for assessing marrow infiltration and extramedullary disease. Early studies show promising sensitivity for detecting bone marrow involvement patterns that correlate with disease burden.
Radiomics — using artificial intelligence to extract quantitative features from standard imaging — may eventually predict genetic subtypes of leukemia from imaging patterns alone, though this remains investigational.
Frequently Asked Questions
Can a CT scan detect leukemia?
A CT scan cannot diagnose leukemia directly — you need a blood smear and bone marrow biopsy for that. However, CT can reveal signs strongly suggestive of leukemia, including diffuse lymphadenopathy, massive splenomegaly, or chloromas. Many leukemia cases are first suspected after an incidental CT finding.
Does leukemia show up on a PET scan?
It depends on the subtype. Aggressive leukemias like ALL and AML (especially chloromas) tend to be FDG-avid and light up on PET. Chronic lymphocytic leukemia is often PET-negative unless Richter transformation has occurred. PET/CT is not used routinely for all leukemia types.
Why did my doctor order an MRI of my brain after a leukemia diagnosis?
Your doctor is checking for central nervous system involvement — leukemia cells can cross the blood-brain barrier and infiltrate the meninges or brain parenchyma. This is especially common in ALL, where CNS-directed therapy is standard. MRI with contrast is the best imaging tool for this, though lumbar puncture is still needed for confirmation.
How often will I need imaging during leukemia treatment?
This varies significantly by leukemia type and treatment phase. During induction chemotherapy for acute leukemia, you may get a chest CT every time you spike a fever. For CLL being monitored with a watch-and-wait approach, imaging may only happen every 6-12 months or when symptoms change. Your hematologist will tailor the schedule to your specific situation.
Is there radiation risk from repeated CT scans during leukemia treatment?
Yes, each CT scan delivers roughly 5-20 mSv of radiation depending on the body region. However, in the context of active leukemia treatment, the benefit of detecting life-threatening infections or disease progression far outweighs this risk. For long-term survivors, especially children, clinicians increasingly prefer MRI or ultrasound when feasible to minimize cumulative radiation exposure.
Key Takeaways
- Imaging doesn’t replace bone marrow biopsy for leukemia diagnosis but is essential for staging, complication management, and response monitoring.
- Each leukemia subtype has characteristic imaging findings — chloromas in AML, mediastinal masses in T-ALL, bulky lymphadenopathy in CLL, and massive splenomegaly in CML.
- CT scans during treatment are most often ordered to evaluate infections in neutropenic patients, not to “check on the leukemia” directly.
- PET/CT is most valuable for detecting Richter transformation in CLL and extramedullary disease in acute leukemias.
- Emerging techniques like whole-body diffusion-weighted MRI may reduce radiation exposure while providing detailed marrow assessment.
